A toxic form of cholesterol accumulates in blood vessels and contributes to atherosclerosis.
Cardiovascular disease is the leading cause of death worldwide. Most treatments slow its progression. Repair Biotechnologies is trying to reverse it by targeting excess cholesterol directly inside liver cells.
Most cardiovascular therapies lower cholesterol or reduce inflammation. A new clinical result takes a different approach: binding a toxic cholesterol byproduct and flushing it out through urine.
Most cardiovascular treatments lower LDL cholesterol or reduce inflammation. A new drug candidate takes a different approach, targeting a toxic cholesterol breakdown product that traps immune cells in artery walls.